In response to the FDA approval of sacituzumab govitecan-hziy for adult patients with metastatic, triple negative breast cancer (TNBC) who received at least two prior therapies for metastatic disease, the panel voted on the addition of sacituzumab govitecan-hziy for this indication.

External request:
Submission from Immunomedics Inc., to recommend the preferred use of sacituzumab govitecan-hziy for patients with mTNBC who previously received at least two prior therapies for metastatic disease.

Based on a review of data and the recent FDA approval, the panel consensus was to include sacituzumab govitecan-hziy as a systemic treatment option for metastatic TNBC. This is a category 2A, other recommended regimen.

The panel consensus did not support a category 1 recommendation.

The following footnote has been included: For adult patients with metastatic, triple negative breast cancer (TNBC) who received at least two prior therapies for metastatic disease.

Reference: